Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral Vector (FLT201) in Subjects With Gaucher Disease (GALILEO-2)

NCT06545136 is registered in ClinicalTrials.gov with Spur Therapeutics as lead sponsor.

NCT NCT06545136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06545136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral Vector (FLT201) in Subjects With Gaucher Disease (GALILEO-2)
Lead sponsor
Spur Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 13, 2024
Completion date
May 31, 2029
Enrollment
75 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

gaucher disease, type 1